

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 9/6/1955
Gender: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Lymphocyte Subset Panel 5 - Total Lymphocyte Enumeration

ARUP test code 0095892

% CD3	97 %	H	(Ref Interval: 62-89)
Absolute CD3	5229 cells/uL	H	(Ref Interval: 660-2200)
% CD4	12 %	L	(Ref Interval: 35-68)
Absolute CD4	673 cells/uL		(Ref Interval: 490-1600)
% CD8	85 %	H	(Ref Interval: 10-46)
Absolute CD8	4587 cells/uL	H	(Ref Interval: 150-1050)
CD4:CD8 Ratio	0.14 ratio	L	(Ref Interval: 0.80-6.17)
% Natural Killer Cells	1 %	L	(Ref Interval: 5-28)
Absolute Natural Killer Cells	57 cells/uL	L	(Ref Interval: 74-620)
% CD19	2 %	L	(Ref Interval: 5-21)
Absolute CD19	124 cells/uL		(Ref Interval: 74-510)
Lymphocyte Subset Panel 5 Information	See Note		

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: Lymphocyte Subset 5, Total Enumeration
 The CD4 cells are Helper T-cells expressing both CD3 and CD4. The CD8 cells are Cytotoxic T-cells expressing both CD3 and CD8. The B-cells express CD19, but not CD3. The NK-cells express either CD16 or CD56 (or both) but not CD3. CD3, CD4, CD8, CD19 and NK-cell percentages are reported as a percent of total lymphocytes. CD4 T-cell levels are a criterion for categorizing HIV-related clinical conditions by the CDC's classification system for HIV infection. The measurement of CD4 T-cell levels has been used to establish decision points for initiating P. jirovecii prophylaxis, antiviral therapy and to monitor the efficacy of treatment. The Public Health Service (PHS) has recommended that CD4 T-cell levels be monitored every three to six months in all HIV-infected persons.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
% CD3	24-067-102401	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Absolute CD3	24-067-102401	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
% CD4	24-067-102401	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Absolute CD4	24-067-102401	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
% CD8	24-067-102401	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Absolute CD8	24-067-102401	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CD4:CD8 Ratio	24-067-102401	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
% Natural Killer Cells	24-067-102401	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Absolute Natural Killer Cells	24-067-102401	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
% CD19	24-067-102401	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Absolute CD19	24-067-102401	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Lymphocyte Subset Panel 5 Information	24-067-102401	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at: